Herceptin's wider use comes closer to EU/US approval
Two days after it filed for approval of Hecerptin for the treatment of early-stage HER2-positive breast cancer in the US through its majority-own biotechnology firm Genentech, Swiss drugmaker Roche has followed suit in the EU, looking to increase the...